Old North State Trust’s CRISPR Therapeutics CRSP Stock Holding History

Old North State Trust’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-150	Closed	-$7K	–	206
2023 Q1	$7K	Hold	150	–	–	﹤0.01%	371
2022 Q4	$6K	Hold	150	–	–	﹤0.01%	369
2022 Q3	$10K	Buy	+150	New	+$10.9K	0.01%	293
2022 Q1	–	Sell	-150	Closed	-$11K	–	173
2021 Q4	$11K	Hold	150	–	–	0.01%	293
2021 Q3	$17K	Hold	150	–	–	0.02%	259
2021 Q2	$24K	Buy	+150	New	+$18.2K	0.02%	252

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Old North State Trust's CRSP Position: Q2 2023 in Review

Old North State Trust sold out of CRISPR Therapeutics (CRSP) in Q2 2023, closing a stake of 150 shares — an estimated $7K sold.

Old North State Trust first reported a position in CRSP in Q2 2021 and held it in 6 quarters. The position peaked at $24K in Q2 2021. 418 funds tracked by Wall St. Rank hold CRSP as of Q2 2023.

Old North State Trust reported no remaining CRISPR Therapeutics position as of Q2 2023 after selling out during the quarter.
Old North State Trust sold 150 CRISPR Therapeutics shares in Q2 2023, an estimated $7K.
Old North State Trust first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 6 quarters.
Old North State Trust's CRISPR Therapeutics position peaked at $24K in Q2 2021.
418 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2023.

Based on Old North State Trust's 13F filing for Q2 2023, filed 22 Aug 2023.